ARTICLE

FindCenter AddIcon

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression

By Yasemin Saplakoglu — 2019

The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).

Read on www.livescience.com

FindCenter Post-Image

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience

Using pharmacokinetic modeling and DMT blood sampling data, we demonstrate that the unique pharmacological characteristics of DMT, which also include a rapid onset and lack of acute tolerance to its subjective effects, make it amenable to administration by target-controlled intravenous infusion.

Article
Andrew R. Gallimore and Rick J. Strassman
2016
FindCenter AddIcon
FindCenter Post-Image

Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents

Taken together, our results suggest that psychedelic microdosing may alleviate symptoms of mood and anxiety disorders, though the potential hazards of this practice warrant further investigation.

Article
Lindsay P. Cameron, Charlie J. Benson, Brian C. DeFelice, Oliver Fiehn, and David E. Olson
2019
FindCenter AddIcon
FindCenter Post-Image

DMT Alters Cortical Travelling Waves

These results support a recent model proposing that psychedelics reduce the ‘precision-weighting of priors’, thus altering the balance of top-down versus bottom-up information passing.

Article
Andrea Alamia, Christopher Timmermann, David J Nutt, Rufin VanRullen, Robin L Carhart-Harris
2020
FindCenter AddIcon
FindCenter Post-Image

Mixing Magic Mushrooms and Meditation Has Long-Term Benefits, Johns Hopkins Study Finds

The benefits of controlled psilocybin use and spiritual practice on people's well-being long outlast the high, researchers find.

Article
Teodora Zareva
2018
FindCenter AddIcon
FindCenter Post-Image

The Trip Treatment

Research into psychedelics, shut down for decades, is now yielding exciting results.

Article
Michael Pollan
2015
FindCenter AddIcon
FindCenter Post-Image

UFC Eyes Psychedelics as Therapy for Fighters’ Brain Injuries

Last month, Ian McCall told HBO’s Real Sports that his 17 years in mixed martial arts led him to a painkiller addiction. “I was medicated and so numbed out from such a young age, I turned into a monster,” he told correspondent David Scott.

Article
Dustin Foote
2021
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Drugs Can Help Treat PTSD Caused by Racism, Discrimination: Researchers

Williams is the co-lead author of a recent retrospective study that found those who tried doses of psilocybin (more commonly known as magic mushrooms), LSD, or MDMA (the pure substance found in Ecstasy or Molly) reported a decrease in trauma symptoms, depression and anxiety after 30 days.

Article
Avis Favaro, Elizabeth St. Philip, Solarina Ho
2021
FindCenter AddIcon
FindCenter Post-Image

How Ecstasy and Psilocybin Are Shaking Up Psychiatry

Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.

Article
Paul Tullis
2021
FindCenter AddIcon
FindCenter Post-Image

MDMA Lauded as ‘Breakthrough’ Therapy for PTSD Patients

The Food and Drug Administration (FDA) has approved the design of two Phase 3 clinical trials of MDMA for treating PTSD, according to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is funding and leading the clinical trials.

Article
Maureen Meehan
2017
FindCenter AddIcon
FindCenter Post-Image

The Interview: MDMA-Therapy Expert Dr. Rick Doblin

The world’s leading advocate for the medicinal use of psychedelics on the ghost of Timothy Leary, why Ecstasy could cure PTSD, and the best place to trip in Boston.

Article
Catherine Elton
2019
FindCenter AddIcon

EXPLORE TOPIC

Psilocybin